Predictive Oncology Inc.
Predictive Oncology Inc. (POAI) Financial Performance & Income Statement Overview
Analyze Predictive Oncology Inc. (POAI) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Predictive Oncology Inc. (POAI) Income Statement & Financial Overview
View the income breakdown for Predictive Oncology Inc. POAI across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $611585.00 | $345686.00 | $278722.00 | $419646.00 |
| Cost of Revenue | $290626.00 | $196919.00 | $317133.00 | $349980.00 |
| Gross Profit | $320959.00 | $148767.00 | -$38411.00 | $69666.00 |
| Gross Profit Ratio | $0.52 | $0.43 | -$0.14 | $0.17 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.78M | $1.83M | $3.15M | $4.31M |
| Operating Expenses | $2.44M | $2.46M | $3.15M | $4.31M |
| Total Costs & Expenses | $2.74M | $2.66M | $3.47M | $4.66M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $573644.00 | $0.00 | $164165.00 | $162565.00 |
| EBITDA | -$1.55M | -$2.31M | -$3.03M | -$4.07M |
| EBITDA Ratio | -$2.53 | -$6.69 | -$10.85 | -$9.71 |
| Operating Income | -$2.12M | -$2.31M | -$3.19M | -$4.24M |
| Operating Income Ratio | -$3.47 | -$6.69 | -$11.44 | -$10.10 |
| Other Income/Expenses (Net) | $22786.00 | $30563.00 | $7986.00 | $17929.00 |
| Income Before Tax | -$2.10M | -$2.28M | -$3.18M | -$4.22M |
| Income Before Tax Ratio | -$3.44 | -$6.61 | -$11.41 | -$10.05 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $5.00 |
| Net Income | -$2.17M | -$3.09M | -$3.18M | -$4.22M |
| Net Income Ratio | -$3.55 | -$8.95 | -$11.41 | -$10.05 |
| EPS | $0.00 | -$0.36 | -$0.68 | -$1.04 |
| Diluted EPS | $0.00 | -$0.36 | -$0.68 | -$1.04 |
| Weighted Avg Shares Outstanding | $5.45M | $8.67M | $4.66M | $4.06M |
| Weighted Avg Shares Outstanding (Diluted) | $5.45M | $6.40M | $4.66M | $4.06M |
The company's financials show resilient growth, with revenue advancing from $419646.00 in Q1 2024 to $611585.00 in Q4 2024. Gross profit remained healthy with margins at 52% in Q4 2024 compared to 17% in Q1 2024. Operating income hit -$2.12M last quarter, sustaining a consistent -347% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.55M. Net income rose to -$2.17M, while earnings per share reached $0.00. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan